In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.
about
Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous dosesCefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndromeSHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacaeIn vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models.In vitro activity of BRL 36650, a new penicillinIn vitro activity of cefepime against multidrug-resistant Gram-negative bacilli, viridans group streptococci and Streptococcus pneumoniae from a cross-Canada surveillance studyIn vitro and in vivo activities of SCE-2787, a new parenteral cephalosporin with a broad antibacterial spectrumComparative activity of cefepime with several antimicrobials against aerobic Gram-negative and Gram-positive organisms isolated from patients across Canada in 1993.Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins.Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjectsPharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment.Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin.Current trends and new perspectives in antibiotic therapy.Pharmacokinetics of the novel cephalosporin cefepime (BMY-28142) in rats and monkeys.Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis.Comparison of antimicrobial efficacy of a fixed dose combination of ceftazidime + sulbactam with ceftazidime and sulbactam alone against five bacteria.In-vitro activity of cefepime and seven other antimicrobial agents against 1518 non-fermentative Gram-negative bacilli collected from 48 Canadian health care facilities. Canadian Afermenter Study Group.Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.
P2860
Q28251630-0F399F4C-0212-4635-AB3E-923CCFFB6A33Q33750327-08457EB7-89F3-47DB-93EA-EF6EF08EC357Q34073514-EBFCAF7A-3442-48BB-9AB8-39014AFFB1BDQ35166038-A1F5F778-55F0-45DA-A818-C40E441CE8A3Q35573832-4714EB25-EC9D-4990-A791-4B40D9F38D67Q35649669-3FBAC129-5FFE-4197-8256-FA1BA2353D07Q35884688-4BF2FF78-AF09-4CBB-956D-155DA819ADF1Q35893006-39F67ED6-2325-4704-82D2-329C26D44B8BQ36753861-9FBF48D6-917C-498C-9C0F-07543C5C20A2Q36757158-190EC581-7175-4CB5-8039-563E546F4379Q36758208-5FD99B13-0E94-4A19-A2D7-ECE15F3FE6E4Q37203973-94FCC758-BB26-40BF-A0CE-96E18ED50C89Q38725018-E3706208-D56F-4F8B-B5E1-934811547477Q39828216-CA97A6D1-B7D9-4B43-89A0-393CD8B2B302Q39879617-97306241-430A-4FD2-9D93-FB4D909986CDQ43236038-2BD01FCB-E66D-44C3-A011-E4E838251FC5Q54070057-6BB32A43-95F7-487F-9692-CE533E309B7FQ54344327-0A4F0CCD-0E29-42B2-8463-9384375BB5B6
P2860
In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
In vitro activity of BMY-28142 ...... a-lactam antimicrobial agents.
@ast
In vitro activity of BMY-28142 ...... a-lactam antimicrobial agents.
@en
type
label
In vitro activity of BMY-28142 ...... a-lactam antimicrobial agents.
@ast
In vitro activity of BMY-28142 ...... a-lactam antimicrobial agents.
@en
prefLabel
In vitro activity of BMY-28142 ...... a-lactam antimicrobial agents.
@ast
In vitro activity of BMY-28142 ...... a-lactam antimicrobial agents.
@en
P2093
P2860
P356
P1476
In vitro activity of BMY-28142 ...... a-lactam antimicrobial agents.
@en
P2093
P2860
P304
P356
10.1128/AAC.27.4.515
P407
P577
1985-04-01T00:00:00Z